PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
79.31%
Cash & equivalents growing 79.31% while AGEN's declined -32.75%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
79.31%
Below half of AGEN's -27.61%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.18%
Below half of AGEN's -23.80%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-6.11%
Below half AGEN's 0.24%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.01%
Higher Other Non-Current Assets Growth compared to AGEN's zero value, indicating worse performance.
-0.83%
0.5-0.75x AGEN's -1.33%. Martin Whitman wonders if there's insufficient reinvestment vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
67.39%
Below half of AGEN's -15.42%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-6.24%
Less than half of AGEN's 46.97%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-81.40%
Exceeding 1.5x AGEN's -2.74%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-14.04%
Less than half of AGEN's 65.31%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.04%
Less than half of AGEN's 3.55%. David Dodd sees far fewer liability expansions relative to competitor.
36.75%
Above 1.5x AGEN's 0.14%. Michael Burry suspects heavy new equity expansion or dilution.
-4.17%
Similar yoy to AGEN's -3.86%. Walter Schloss sees parallel earnings retention vs. competitor.
-5.37%
Less than half of AGEN's 10.10%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
105.08%
Below half AGEN's -195.14%. Michael Burry sees potential underperformance in building shareholder capital.
67.39%
Below half AGEN's -15.42%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-79.31%
Less than half of AGEN's 86.52%. David Dodd sees better deleveraging or stronger cash buildup than competitor.